NSD1、NSD2 和 NSD3 组蛋白甲基转移酶在实体瘤中的作用。
The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
机构信息
Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 303 E. Superior Street, Chicago, IL, 60611, USA.
Department of Natural and Applied Sciences, Nexus Institute of Research and Innovation (NIRI), Sitapakha, Mahalaxmi-4, Lalitpur, Bagmati, 44700, Nepal.
出版信息
Cell Mol Life Sci. 2022 May 9;79(6):285. doi: 10.1007/s00018-022-04321-2.
NSD1, NSD2, and NSD3 constitute the nuclear receptor-binding SET Domain (NSD) family of histone 3 lysine 36 (H3K36) methyltransferases. These structurally similar enzymes mono- and di-methylate H3K36, which contribute to the maintenance of chromatin integrity and regulate the expression of genes that control cell division, apoptosis, DNA repair, and epithelial-mesenchymal transition (EMT). Aberrant expression or mutation of members of the NSD family is associated with developmental defects and the occurrence of some types of cancer. In this review, we discuss the effect of alterations in NSDs on cancer patient's prognosis and response to treatment. We summarize the current understanding of the biological functions of NSD proteins, focusing on their activities and the role in the formation and progression in solid tumors biology, as well as how it depends on tumor etiologies. This review also discusses ongoing efforts to develop NSD inhibitors as a promising new class of cancer therapeutic agents.
NSD1、NSD2 和 NSD3 构成了核受体结合 SET 域（NSD）家族的组蛋白 3 赖氨酸 36（H3K36）甲基转移酶。这些结构相似的酶单甲基化和二甲基化 H3K36，有助于维持染色质完整性，并调节控制细胞分裂、细胞凋亡、DNA 修复和上皮-间充质转化（EMT）的基因表达。NSD 家族成员的异常表达或突变与发育缺陷和某些类型的癌症的发生有关。在这篇综述中，我们讨论了 NSD 改变对癌症患者预后和治疗反应的影响。我们总结了目前对 NSD 蛋白生物学功能的理解，重点介绍了它们的活性及其在实体瘤生物学中的形成和进展中的作用，以及如何依赖于肿瘤病因。这篇综述还讨论了正在努力开发 NSD 抑制剂作为一种有前途的新型癌症治疗剂。
Zotero 插件